3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Thoracic
2
Genitourinary
2
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
166
Cisplatin
112
Cetuximab
76
Nivolumab
52
Carboplatin
51
Fluorouracil
48
Paclitaxel
42
Docetaxel
37
Gemcitabine
30
Radiotherapy
28
Capecitabine
19
Cyclophosphamide
18
durvalumab
17
Injections
17
lenvatinib
16
atezolizumab
16
cemiplimab
15
spartalizumab
13
fludarabine
13
avelumab
12
Ipilimumab
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
11
Oxaliplatin
10
Gefitinib
10
tremelimumab
9
Drug Therapy
9
tislelizumab
8
epacadostat
8
budigalimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
bemarituzumab
×
Head & Neck
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled